An Ottawa tech company with the goal of revolutionizing the hearing health industry says it’s raised $6 million in series-A financing that will help it expand sales in North America and Europe.
Clearwater Clinical, founded in 2005, recorded a triple-digit increase in sales last year, the company said Thursday in announcing the financing.
Its signature product is named the Shoebox Audiometry, which the company says is the world’s first clinically-validated tablet-based audiometer. It makes it possible for virtually anyone in a quiet environment to perform tests leading to the early detection of hearing-related conditions.
(Sponsored)
Iconic spaces, lasting impressions
The Canadian Museum of History and the Canadian War Museum offer more than beautiful spaces; they provide meaningful settings celebrating heritage, culture and design. An architectural landmark overlooking Parliament Hill
The story behind Glenview Homes’ 2025 GOHBA award-winning Reveli floor plan
When Glenview Homes’ Design and Drafting Manager Eno Reveli sat down to design a new production floor plan, he wasn’t thinking about awards or show homes. He was thinking about
Clearwater’s client base includes customers involved in industrial workplace testing, retail, pharmaceuticals and hearing-care multinationals.
“Hearing loss is the world’s leading disability, affecting almost 640 million people globally, and yet there has been very little innovation to audiometers in the last 50 years,” said Clearwater Clinical CEO Michael Weider in a statement. “We believe that it is possible to … make it possible for every person on the planet to have access to a hearing test.”
The latest funding round was led by Toronto-based Whitecap Venture Partners and BDC Capital Healthcare Venture Fund. It brings Clearwater Clinical’s total funding to date to $9.5 million.
Alongside Shoebox, Clearwater operates a second division, Modica, which is medical camera app designed for physicians to securely record, archive, manage and share photos and videos directly from their iPhone.
